In this High Risk/Recurrent/Advanced PCa virtual group recording from September 2018, Al Pfadt, a castrate resistant PCa patient with clear lymph node involvement, reviews his success using monotherapy apalutamide (Erleada). Al’s genitourinary medical oncologist is the highly regarded William Oh at Mount Sinai.
The clear advantage of any monotherapy anti-androgen is that it drops the LHRH, androgen deprivation drug. In Al’s case, his PSA continues to fall in the face of a rising testosterone level.